CERN - Cerner Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
71.38
-0.45 (-0.63%)
At close: 4:00PM EDT

71.38 0.00 (0.00%)
After hours: 4:18PM EDT

Stock chart is not supported by your current browser
Previous Close71.83
Open71.28
Bid70.74 x 1300
Ask75.14 x 1100
Day's Range71.30 - 71.98
52 Week Range48.78 - 76.47
Volume1,242,004
Avg. Volume2,406,192
Market Cap22.727B
Beta (3Y Monthly)0.81
PE Ratio (TTM)39.44
EPS (TTM)1.81
Earnings DateOct 23, 2019 - Oct 28, 2019
Forward Dividend & Yield0.72 (1.02%)
Ex-Dividend Date2019-06-17
1y Target Est74.56
Trade prices are not sourced from all markets
  • Starboard Value shrinks stake in Cerner
    American City Business Journals

    Starboard Value shrinks stake in Cerner

    Now that Starboard Value has two seats on Cerner's board and a say in operational and cost structures, the activist investor is decreasing its already small stake in the health IT company.

  • Cerner jumps into senior living with latest venture
    American City Business Journals

    Cerner jumps into senior living with latest venture

    Cerner has partnered with a planned wellness community development company to provide health care services to seniors using the company's technology.

  • Does Cerner Corporation (NASDAQ:CERN) Create Value For Shareholders?
    Simply Wall St.

    Does Cerner Corporation (NASDAQ:CERN) Create Value For Shareholders?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • Cerner exec: New partnership will use data to drive down drug costs
    American City Business Journals

    Cerner exec: New partnership will use data to drive down drug costs

    The pilot program and partnership between Cerner and Duke Clinical Research Institute has the potential to make clinical research more cost effective through automating and analyzing data collection.

  • 3 Keys to Investing in Next-Gen Healthcare Stocks
    InvestorPlace

    3 Keys to Investing in Next-Gen Healthcare Stocks

    Picture a bizarre clothing store for a moment …Source: Shutterstock You walk in. An employee sizes you up and asks you if there's anything in particular you're looking for. After learning that you're a size "large" and that you'd like some new dress shirts, the employee takes you to a table covered with them. All of the shirts are the same size. All XL, extra-large."Strange," you think, and go to another table covered with shirts. All the shirts are the same size. All XL.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"Stranger," you think, and go to another table covered with shirts. Once again, all the shirts are the same size. All XL.Sensing your confusion, the employee explains the store's "one size fits all" policy. The owners know people come in many shapes and sizes, but XL is the only size of clothes they can get from their suppliers.You walk out of the "one size fits all" store, thinking it's one of the most ridiculous things you've ever seen.A "one size fits all" clothing store isn't much different than America's healthcare system.Lacking the resources to treat us as individuals -- with different genetic makeups, different diets, and living in different environments -- doctors frequently resort to treating patients with "one size fits all" procedures and medicines. And since most doctors rush patients in and out of the office to boost profits, the pressure to use sub-par, "one size fits all" treatments is massive.Don't get me wrong: Our approach to health and medicine is light years ahead of where it was in the 1800s. Bloodletting is no longer a "go to" move for doctors.However, many of the decisions made by today's healthcare professionals will look medieval when compared to the treatments of the near future. They simply don't take into account that every case is different -- that we are all unique. Take the drug commercials you see on television … which go on to list lots of horrible side effects of popular drugs (which don't work for everyone who takes them).Soon, we'll say goodbye to those types of treatments. That's because the age of customized, "precision" healthcare is getting started. The result will be a massively improved healthcare system … and some of the biggest wealth building opportunities of your life.In today's essay, I'll describe the three key innovations that will take us into the age of precision medicine. Investors will want to pay attention. In America, we spend $3.5 trillion -- about 18% of GDP -- on healthcare. When something big happens in healthcare, it creates giant ripple effects in the economy that enrich those who know what's happening. Trillion-Dollar Innovation 1: Genome SequencingEvery cell in your body has a set of genetic instructions that dictate what you look like, what your athletic abilities are, what your mental abilities are, what diseases you're likely to get, and dozens of other key things that make you YOU.This set of instructions is called your genome. Determining exactly what your genome says is a process called genome sequencing.In 2003, an international research organization called The Human Genome Project sequenced a human genome for the first time. The project's price tag was an enormous $3 billion.Thanks to incredible advances in computing power, that same sequencing can be performed today for less than $1,000. And in a few years the price will be as low as a dinner for two.Genome sequencing is a critical part of precision medicine because it allows medical professionals to get an incredibly detailed analysis of who you are. As a result of this information, doctors can recommend treatments that are right for you.Sixteen years ago, getting this kind of detailed information was prohibitively expensive. But now that costs are down more than 99% and poised to go down even more, genome sequencing is about to go mainstream.Genetic testing will become part of regular medical care … just like taking your pulse and your blood pressure. It's going to usher in an era of much more effective healthcare. In large part to innovation 2 … Trillion-Dollar Innovation 2: Digital Patient RecordsIt's one thing to have lots of information. It's an entirely different -- and more valuable -- thing to be able to analyze that information and use it to make quality decisions.This is where digital patient records come in.Genome sequencing will produce vast amounts of information that will need to be stored and analyzed. Just as the processing power of our computers has increased by leaps and bounds since 2003, our ability to collect and store information has increased as well. This continued growth is a key part of precision medicine. That's because genome sequencing is going to generate a stupendous amount of information.It is predicted that the amount of storage capacity for all human genome data will increase to 40 exabytes by 2025. To put that into perspective, experts believe all videos on YouTube will require 1-2 exabytes of storage and Twitter will require .001 to .017 exabytes.As for analyzing all that data, we come to Innovation 3 … Trillion-Dollar Innovation 3: AI DoctorsAs you can guess, we're not going to sift through some of the world's largest data sets with a pen and paper in hand.We're going to use artificial intelligence (AI) to perform advanced data analysis. AI programs will sift through data to identify treatments that work for patients with specific genetic conditions.These programs will be able to do more "thinking" in one minute than millions of doctors could do in a decade. It's going to revolutionize healthcare.In fact, I believe that within the next 30 years, AI will know how various combinations of molecules will affect patients on the individual level. We'll have giant databases of patients and their genetic makeups … and we'll be able to test new drugs with computer simulations. The time it takes to devise, test, and produce new life-saving drugs will be massively condensed. Plus, the cost of doing it all will plummet.We'll have vast databases of human genomes and the ability to create and test new customized treatments in seconds. It could easily become the most valuable technology on the planet. Again, this is many years away, but I believe it's going to happen. Summing UpOne size fits allThanks to the technological limitations of the past, our healthcare system is based on treatments that are not tailored to your genetic makeup. We're using "shotgun" approaches instead of targeted approaches.However, thanks to cheap and widespread genome sequencing, digital record keeping, and artificial intelligence, we're about to enter an amazing era of precision, personalized medicine.Over the next 20 years, the healthcare system we know and don't love will change dramatically. We'll look back at some of today's treatments as medieval.Remember: In America, we spend $3.5 trillion -- about 18% of GDP -- on healthcare. When something big happens in the industry, it creates giant ripple effects. That's why the precision medicine revolution is one of the greatest wealth building opportunities of your life.The opportunities are not in the old school big pharma names like Johnson & Johnson. They are in precision medicine and the technologies that will enable it.Everything from digital records company Cerner (NASDAQ:Cern) to gene testing pioneer Illumina (NASDAQ:ILMN) to contract research services firm IQVIA Holdings (NYSE:IQV) will take the lead in the future of precision medicine.And keep an eye on the IPO market here as well. We'll see waves of early stage companies going public … many with the potential to not only revolutionize medicine, but revolutionize your net worth as well.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 7 Services Stocks to Buy for the Rest of 2019 * 6 Stocks to Buy and 1 to Sell Based on Insider Trading The post 3 Keys to Investing in Next-Gen Healthcare Stocks appeared first on InvestorPlace.

  • GlobeNewswire

    Cerner, Duke Clinical Research Institute Launch New Solution to Innovate Clinical Research

    Cerner Corporation (CERN), a global health platform and innovation company, has announced the development of the Cerner Learning Health NetworkSM to help clinicians more easily and efficiently gain health insights and guide care. Cerner aims to automate data collection from multiple sources, including the electronic health record (EHR), to rapidly give medical researchers access to important information that has the potential to transform patient care. Through combined technology and expertise, Cerner and the Duke Clinical Research Institute (DCRI) have joined together to pilot the Cerner Learning Health Network and innovate clinical research registries in the process.

  • VA transfers 23.5M patient health records to Cerner’s KC data center
    American City Business Journals

    VA transfers 23.5M patient health records to Cerner’s KC data center

    The transfer comes as part of Cerner's $16.1 billion contract to develop a new electronic health record system to replace the VA's existing offering — and be interoperable with Defense Department data.

  • OptimizeRx (OPRX) to Report Q2 Earnings: What's in Store?
    Zacks

    OptimizeRx (OPRX) to Report Q2 Earnings: What's in Store?

    OptimizeRx's (OPRX) second-quarter 2019 results are likely to benefit from increased sales of core financial and brand messaging products.

  • Cerner's Amazon cloud deal will deliver 'pretty disruptive' solutions, capabilities
    American City Business Journals

    Cerner's Amazon cloud deal will deliver 'pretty disruptive' solutions, capabilities

    Cerner chose Amazon Web Services as its preferred cloud provider, creating a partnership that could drive health IT innovation.

  • GlobeNewswire

    Cerner Leads New Era of Health Care Innovation

    Cerner Corporation (CERN), a global health platform and technology company, today announced a multi-faceted, strategic collaboration with Amazon Web Services, Inc. (AWS), an Amazon.com company, to accelerate health care innovation across the globe. As part of this agreement, Cerner is naming AWS its preferred cloud provider.

  • Thomson Reuters StreetEvents

    Edited Transcript of CERN earnings conference call or presentation 24-Jul-19 8:30pm GMT

    Q2 2019 Cerner Corp Earnings Call

  • GuruFocus.com

    Parnassus Fund Comments on Cerner

    Guru stock highlight Continue reading...

  • GuruFocus.com

    Parnassus Fund 2nd Quarter Commentary

    Discussion of markets and holdings Continue reading...

  • Hot IPO company Livongo's CEO was once a fierce rival with its founder
    American City Business Journals

    Hot IPO company Livongo's CEO was once a fierce rival with its founder

    On the day of Livongo's soaring IPO, CEO Zane Burke recalls his once fierce rivalry with founder and chairman Glen Tullman.

  • Cerner's voluntary separations achieve $40M of its targeted $200M in cuts
    American City Business Journals

    Cerner's voluntary separations achieve $40M of its targeted $200M in cuts

    Cerner's quarterly report reflects activist investor Starboard Value LP's influence, as it focuses on aggressively improving its operating margins.

  • MDRX or CERN: Which Is the Better Value Stock Right Now?
    Zacks

    MDRX or CERN: Which Is the Better Value Stock Right Now?

    MDRX vs. CERN: Which Stock Is the Better Value Option?

  • Cerner (CERN) Q2 Earnings Beat Estimates, Revenues Miss
    Zacks

    Cerner (CERN) Q2 Earnings Beat Estimates, Revenues Miss

    Cerner (CERN) Q2 results benefit from higher revenues, gains in Licensed software, Professional and Managed services units, and gross margin expansion.

  • Cerner Delivers As Expected in the Second Quarter
    Motley Fool

    Cerner Delivers As Expected in the Second Quarter

    The healthcare technology provider met its revenue guidance and beat its adjusted earnings guidance, thanks primarily to growth in its services business.

  • Cerner Corp (CERN) Q2 2019 Earnings Call Transcript
    Motley Fool

    Cerner Corp (CERN) Q2 2019 Earnings Call Transcript

    CERN earnings call for the period ending June 30, 2019.

  • Cerner (CERN) Q2 Earnings Top Estimates
    Zacks

    Cerner (CERN) Q2 Earnings Top Estimates

    Cerner (CERN) delivered earnings and revenue surprises of 3.13% and -0.40%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Cerner Reports Second Quarter 2019 Results

    KANSAS CITY, Mo., July 24, 2019 -- Cerner Corporation (Nasdaq: CERN) today announced results for the 2019 second quarter that ended June 29, 2019. Bookings in the second.

  • Cerner-supported company faces scrutiny over medical billing, technology
    American City Business Journals

    Cerner-supported company faces scrutiny over medical billing, technology

    Cerner invested $266 million in Essence Group Holdings Corp. and its medical technology arm Lumeris in July 2018. Now, the St. Louis-based companies are facing a whistleblower lawsuit and a troubling audit by the U.S. Department of Health and Human Services.

  • Do Directors Own Cerner Corporation (NASDAQ:CERN) Shares?
    Simply Wall St.

    Do Directors Own Cerner Corporation (NASDAQ:CERN) Shares?

    Every investor in Cerner Corporation (NASDAQ:CERN) should be aware of the most powerful shareholder groups. Generally...

  • What's in the Offing for Cerner's (CERN) Earnings in Q2?
    Zacks

    What's in the Offing for Cerner's (CERN) Earnings in Q2?

    Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner's (CERN) Q2 earnings. However, expected decline in bookings is likely to be a dampener.